OncoImmunology · 2012 · 377 citations · 29 references
Life SciencesImmunologyOncologyAutophagyImmunoregulationSignal TransductionAutophagy In CancerAutophagy In Stress ResponsesAutophagy ModulationAutophagy Signaling PathwaysInflammation-associated CarcinogenesisInflammatory SignalingCancer Signaling PathwaysCarcinogenesis InhibitionIndoleamine 2, 3-Dioxygenase PathwayInflammatory Signal TransductionPeripheral T Cell ToleranceTryptophan BiosynthesisTryptophan MetabolismTryptophan Requirement
Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO) alters inflammation and favors T-cell tolerance in cancer, but the underlying molecular mechanisms remain poorly understood. The integrated stress response kinase GCN2, a sensor of uncharged tRNA that is activated by amino acid deprivation, is recognized as an important effector of the IDO pathway. However, in a mouse model of inflammatory carcinogenesis, ablation of Gcn2 did not promote resistance against tumor development like the absence of IDO does, implying the existence of additional cancer-relevant pathways that operate downstream of IDO. Addressing this gap in knowledge, we report that the IDO-mediated catabolism of tryptophan also inhibits the immunoregulatory kinases mTOR and PKC-Θ, along with the induction of autophagy. These effects were relieved specifically by tryptophan but also by the experimental agent 1-methyl-D-tryptophan (D-1MT, also known as NLG8189), the latter of which reversed the inhibitory signals generated by IDO with higher potency. Taken together, our results implicate mTOR and PKC-Θ in IDO-mediated immunosuppressive signaling, and they provide timely insights into the unique mechanism of action of D-1MT as compared with traditional biochemical inhibitors of IDO. These findings are important translationally, because they suggest broader clinical uses for D-1MT against cancers that overexpress any tryptophan catabolic enzyme (IDO, IDO2 or TDO). Moreover, they define mTOR and PKC-Θ as candidate pharmacodynamic markers for D-1MT responses in patients recruited to ongoing phase IB/II cancer trials, addressing a current clinical need.
29
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations
Medicine, Immunology, Oncology +14
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz, Ulrike Litzenburger, Felix Sahm et al. · Nature · 2011 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +13